Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015

GLP-1 Agonists in Type 1 Diabetes Mellitus.

OBJECTIVE To review the use of GLP-1 agonists in patients with type 1 diabetes mellitus (T1DM). DATA SOURCES A search using the MEDLINE database, EMBASE, and Cochrane Database was performed through March 2016 using the search terms glucagon-like peptide 1 (GLP-1) agonists, incretin, liraglutide, exenatide, albiglutide, dulaglutide, type 1 diabetes mellitus STUDY SELECTION AND DATA EXTRACTIO...

Drugs for diabetes : part 6 GLP - 1 receptor agonists

Br J Cardiol 2011;18:167−9 T glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of injected drugs for the treatment of type 2 diabetes. They mimic the action of GLP-1 and increase the incretin effect in patients with type 2 diabetes, stimulating the release of insulin. They have additional effects in reducing glucagon, slowing gastric emptying, and inducing satiety. In clinical p...

GLP-1 receptor agonists and heart failure in diabetes.

The prevalence of heart failure (HF) is increasing in patients with type 2 diabetes (T2D), and glucose-lowering agents have distinctive effects on the risk of developing HF that requires hospitalization. Such an increased risk has been consistently reported with thiazolidinediones (glitazones) and perhaps also with the dipeptidyl peptidase (DPP)-4 inhibitor saxagliptin (at least in SAVOR - TIMI...

GLP-1 for type 2 diabetes.

Glucagon-like peptide-1 (GLP-1)-based therapy of type 2 diabetes is executed either by GLP-1 receptor agonists, which stimulate the GLP-1 receptors, or by dipeptidyl peptidase-4 (DPP-4) inhibitors, which prevent the inactivation of endogenous GLP-1 thereby increasing the concentration of endogenous active GLP-1. GLP-1 activates pancreatic receptors resulting in improved glycemia through glucose...